JP2019535791A - 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク - Google Patents

血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク Download PDF

Info

Publication number
JP2019535791A
JP2019535791A JP2019528540A JP2019528540A JP2019535791A JP 2019535791 A JP2019535791 A JP 2019535791A JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019535791 A JP2019535791 A JP 2019535791A
Authority
JP
Japan
Prior art keywords
insulin
subject
risk
treatment
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019528540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535791A5 (enExample
Inventor
ペア・クヌード・クリステンセン
トゥエ・ヨハンセン
シモン・スキブステッド
カイサ・クヴィスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2019535791A publication Critical patent/JP2019535791A/ja
Publication of JP2019535791A5 publication Critical patent/JP2019535791A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019528540A 2016-11-28 2017-11-28 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク Withdrawn JP2019535791A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16200993.0 2016-11-28
EP16200993 2016-11-28
EP17162803.5 2017-03-24
EP17162803 2017-03-24
EP17174687 2017-06-07
EP17174687.8 2017-06-07
PCT/EP2017/080603 WO2018096163A1 (en) 2016-11-28 2017-11-28 Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications

Publications (2)

Publication Number Publication Date
JP2019535791A true JP2019535791A (ja) 2019-12-12
JP2019535791A5 JP2019535791A5 (enExample) 2020-12-17

Family

ID=60702634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528540A Withdrawn JP2019535791A (ja) 2016-11-28 2017-11-28 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク

Country Status (6)

Country Link
US (1) US11673933B2 (enExample)
EP (1) EP3544682A1 (enExample)
JP (1) JP2019535791A (enExample)
CN (1) CN110099719A (enExample)
MA (1) MA46890A (enExample)
WO (1) WO2018096163A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544682A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
JP7193455B2 (ja) 2016-11-28 2022-12-20 ノヴォ ノルディスク アー／エス 心血管状態におけるインスリンデグルデク
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
US20230158234A1 (en) * 2021-11-22 2023-05-25 Colleen Cook Method of Insulin Administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516076A (ja) * 2013-03-20 2016-06-02 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
JP2016519127A (ja) * 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
AU2013241776B2 (en) * 2012-03-28 2017-11-02 Sanofi-Aventis Deutschland Gmbh Basal insulin therapy
EP3544682A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516076A (ja) * 2013-03-20 2016-06-02 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
JP2016519127A (ja) * 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EINHORN, D. ET AL.: "PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH IN", ENDOCRINE PRACTICE, vol. 21, no. 8, JPN6021038617, 2015, pages 917 - 926, XP009193848, ISSN: 0004981268, DOI: 10.4158/EP14523.OR *
FREEMANTLE, N. ET AL.: "IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately", DIABETES THERAPY, vol. 6, no. 4, JPN6021038619, 2015, pages 573 - 591, XP055444045, ISSN: 0004981269, DOI: 10.1007/s13300-015-0142-y *
KAKU, K., EID, M. A.: "Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes", JOURNAL OF DIABETES INVESTIGATION, vol. 6, no. 6, JPN6021038621, 2015, pages 610 - 619, XP093104934, ISSN: 0004838383, DOI: 10.1111/jdi.12348 *
MARSO, S. P. ET AL.: "Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in P", AMERICAN HEART JOURNAL, vol. 179, JPN6022031519, September 2016 (2016-09-01), pages 175 - 183, ISSN: 0004981270 *
久保 敬二: "インスリングラルギンと経口血糖降下薬の併用療法に関する検討", PROGRESS IN MEDICINE, vol. 第28巻, 第11号, JPN6023003574, 2008, pages 2757 - 2761, ISSN: 0004981272 *
佐藤 淳子 ほか: "2型糖尿病の強化インスリン療法におけるNPHインスリンからインスリンデテミルへの切り替え効果—18ヵ月間の", 糖尿病, vol. 第54巻, 第5号, JPN6023003573, 2011, pages 344 - 348, ISSN: 0004981271 *

Also Published As

Publication number Publication date
CN110099719A (zh) 2019-08-06
US20200181222A1 (en) 2020-06-11
US11673933B2 (en) 2023-06-13
MA46890A (fr) 2021-04-28
WO2018096163A1 (en) 2018-05-31
EP3544682A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
Aroda et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial
AU2012328388B2 (en) Treatment protocol of diabetes type 2
US12233114B2 (en) Method for treating diabetes
RU2768283C2 (ru) Семаглутид при сердечно-сосудистых состояниях
Hollander et al. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
KR20140033030A (ko) ２형 진성 당뇨병 환자에서 저혈당증의 예방
JP2019535791A (ja) 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
WO2018096164A1 (en) Insulin degludec for treating diabetes
Freeman Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
CN108883159A (zh) 用于糖尿病性足溃疡的利拉鲁肽
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230524